Meliodays and Celanese Collaborate on Hormone-Free IUD for Menstrual Pain Relief

• Celanese’s VitalDose^® Drug Delivery Platform will facilitate a long-lasting, patient-focused formulation for Meliodays’ IUD design.

MUNICH, July 29, 2025 — Meliodays Medical and Celanese Corporation (NYSE: CE) have entered into an agreement concerning Meliodays’ pre-clinical development of MelioOne^®, a first-of-its-kind hormone-free, non-contraceptive intrauterine device (IUD) intended to provide localized relief from menstrual pain. MelioOne^® combines Celanese’s well-established VitalDose^® Drug Delivery Platform with Meliodays’ innovative IUD design and a non-hormonal active pharmaceutical ingredient (API).

“Over 80% of menstruating individuals experience period pain and cramps,” states Simone Sabbione, CEO and Co-Founder of Meliodays. “Our partnership with Celanese represents the initial milestone in our goal to transform menstrual pain management. Our localized release mechanism targets pain directly at its source, thereby avoiding the systemic side effects frequently associated with oral pain medication. Considering the significant impact of period pain on work, school, and social life, we are proud to collaborate with Celanese to empower menstruating women to experience a natural cycle without compromising their daily lives.”

“We are pleased to be partnering with Meliodays in the early stages of developing an IUD, with the hope that it will eventually become a healthcare provider-prescribed treatment option for women suffering from menstrual pain,” says Brian Duke, Sr. Marketing Manager of Pharmaceutical Solutions at Celanese. “The Celanese team is proud that the VitalDose^® Drug Delivery Platform has been incorporated into our customers’ patient-centric therapies, delivering convenient and effective treatment for women for a considerable time. We are committed to further expanding its application in therapies for women and in any situation where sustained drug delivery offers benefits.”

The VitalDose^® Drug Delivery Platform delivers dependable, controlled-release performance for a diverse array of molecule types and boasts a substantial track record of use in approved parenteral drug products within the United States and Europe. It has been utilized in patient-centered dosage forms, facilitating women’s health treatments for over two decades.

About Meliodays Medical

GmbH is a young pharmaceutical company focused on developing a novel hormone-free, local treatment for menstrual pain. Meliodays Medical is developing MelioOne^®, the first hormone-free, localized solution designed to treat menstrual pain without systemic side effects, addressing a significant unmet medical need. Through its innovative healthcare solutions, Meliodays is paving the way for menstruating individuals to experience an improved quality of life, enabling them to have pain-free periods without disrupting their menstrual cycle. For more information, please visit and follow us on or

About Celanese

is a global leader in chemistry, producing specialty materials used across most major industries and consumer applications. Our businesses leverage our chemistry, technology, and commercial expertise to create value for our customers, employees, and shareholders. We support by responsibly managing the materials we create and expanding our portfolio of sustainable products to meet customer and societal demand. We strive to make a positive impact in our communities and to foster inclusivity across our teams. Celanese Corporation is a Fortune 500 company with over 11,000 employees worldwide and $10.3 billion in net sales in 2024. For more information about Celanese Corporation and its product offerings, visit .